TY - JOUR
AR - DDA-2020-1-104
TI - Ribonucleases and Immunoribonucleases as Potential Modalities of Anticancer Therapy
AU - Monika , Kowalik
AU - Magdalena, Witkowska
AU - Piotr, Smolewski
JO - Drug and Drug Abuse
PY - 2020
DA - Thu 10, Sep 2020
SN - 2674-5062
DO - http://dx.doi.org/10.31487/j.DDA.2020.01.04
UR - https://www.sciencerepository.org/ribonucleases-and-immunoribonucleases-as-potential-modalities-of-anticancer-therapy_DDA-2020-1-104 
KW - Rana pipiens, onconase, r-amphinase, ribonuclease, immunoRNases, apoptosis, anticancer properties
AB - A novel approach of antitumor treatment, that involves targeting RNA either using specific antisense
oligonucleotides or cytostatic/cytotoxic ribonucleases (RNases), is being promoted. Among recently
described cytotoxic RNases, amphibian RNases, including ranpirnase (onconase; ONC) and Amphinase (rAmph), are promising anticancer agents. They manifest strong antitumor effects and act synergistically with
several cytostatics. Recently, rapidly developed proteins by engineering of RNases, displayed cytotoxic
activity against several types of malignant cells. Most recent data show the role of microRNAs in mediating
tumor progression, opening a new field of possible molecular targets for RNases. This review summarizes
the current status of those RNases and immunoRNases as promising novel anticancer therapeutics.